LVAD Beneficial Even For Patients With Most Severe Heart Failure
Implantation of a left ventricular assist device (LVAD) can dramatically improve the survival of patients with advanced heart failure, especially those being […]
World's Largest Resource for Cardiovascular Perfusion
Implantation of a left ventricular assist device (LVAD) can dramatically improve the survival of patients with advanced heart failure, especially those being […]
Remdesivir and its main active metabolite GS‐441524 are rapidly eliminated from the perfusate by the CytoSorb® adsorber device in vitro. This should be considered in patients for whom both therapies are indicated, and simultaneous application should be avoided. In general, plasma levels of therapeutic drugs should be closely monitored under concurrent CytoSorb® therapy.
Among patients at risk of postoperative kidney injury undergoing major abdominal surgery, use of HES for volume replacement therapy compared with 0.9% saline resulted in no significant difference in a composite outcome of death or major postoperative complications within 14 days after surgery.